In Brief This Week: Danaher; Sequenom; Complete Genomics; PerkinElmer; GnuBio; Novozymes, Morphosys; OGI | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher's board of directors approved a quarterly dividend of $.025 per share payable on Jan. 27, 2012 to holders of record on Dec. 30, 2011.


Sequenom said this week that it has been upgraded from the Nasdaq Global Market to the Nasdaq Global Select Market. It will continue to trade under the ticker symbol "SQNM" and will transfer its listing starting Jan. 3, 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.